ArticleCardiovascular risk profile of veteran men beginning androgen deprivation therapy
Section snippets
Data sources and participants
This cross-sectional, correlational study is a secondary analysis of a dataset utilized by Daskivich et al, which received institutional review board (IRB) approval (VA IRB #0003- Creation of a Prostate Cancer Specific Comorbidity Index).14 The primary analysis used the California Cancer Registry to identify all men newly diagnosed with prostate cancer at the Greater Los Angeles and Long Beach Veterans Affairs Medical Centers between 1997 and 2004. Medical records were reviewed to ascertain
Results
Clinical and demographic characteristics of our sample are shown in Table 1. Of the 375 participants in the sample, 147 (39%) were ages 66 to 75 at diagnosis, 109 (29%) were ages 76 to 85, and 84 (22%) were ages 56 to 65. Thirty-five men, approximately 9% of the sample, were either <56 (n = 25) or >85 (n = 10) at diagnosis. Men outside of the 60s age range were included in this analysis to give a comprehensive view of the cardiovascular risks of men with prostate cancer. The majority of men
Discussion
Our results indicate that men receiving ADT are at an increased risk of CVD before treatment begins, which may be exacerbated by the detrimental side effects of ADT. The literature suggests that men receiving ADT are at higher risk for dyslipidemia, particularly an increase in harmful low-density lipoprotein and decreased arterial compliance.4, 8 In addition, men are susceptible to hypertension, which can be exacerbated by smoking and increased BMI.7, 8, 9
Younger men (<56 years), seem to have
Conclusion
By analyzing the cardiovascular comorbidities of veteran men beginning ADT therapy, the evidence suggests men face an elevated risk of developing CVD as a result of ADT on two fronts: Age and ethnicity. Older (>56) tended to have chronic comorbidities, whereas younger men had comorbidities that were easier to modify. Men who identify as Hispanic/other/unknown tended to have higher total cholesterol, whereas men with a high PSA tended to have a SBP of >120 mmHg. Lifestyle changes coupled with
Acknowledgments
The authors thank the UCLA School of Nursing; UCLA David Geffen School of Medicine, Department of Urology; and Timothy Daskivich, MD-UCLA David Geffen School of Medicine, Department of Urology.
References (26)
Side effects of androgen deprivation therapy: monitoring and minimizing toxicity
Urology
(2003)- et al.
Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism
Eur Assoc Urol
(2012) - et al.
Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy
Int J Radiat Oncol Biol Phys
(2005) - et al.
Effect of physical activity and sedentary behavior on serum prostate-specific antigen concentrations: results from the National Health and Nutrition Examination Survey (NHANES), 2003-2006
Mayo Clin Proc
(2013) - et al.
National practice patterns and time trends in androgen ablation for localized prostate cancer
J Natl Cancer Inst
(2003) - et al.
Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial
Eur Urol
(2009) Measuring hot flashes in men treated with hormone ablation therapy: an unmet need
Urol Nurs
(2006)- et al.
Long-term combined androgen blockade along for localized prostate cancer
Mol Urol
(1999) - et al.
Androgen-deprivation therapy in prostate cancer and cardiovascular risk
CA Cancer J Clin
(2010) - et al.
Androgen deprivation therapy–managing side effects
Aust Fam Physician
(2008)